Assurex Health offers GeneSight, a treatment-decision-support test powered by CPGx™, its proprietary combinatorial pharmacogenomics technology, which measures multiple genomic variants and weights them together to provide genetically-driven medication information for each patient. The company recently enhanced the GeneSight Psychotropic test to give providers an expanded range of options for treating depression, anxiety, bipolar disorder, PTSD, schizophrenia and other behavioral health conditions. To date more than 14,000 healthcare providers have used GeneSight to help make treatment decisions for over 230,000 patients across the country. Led by President and CEO Virginia C. Drosos, Assurex will use additional funding to continue to increase adoption of GeneSight. The company also serves chronic pain conditions through its treatment decision support offerings. Assurex Health provides healthcare providers with GeneSight, a treatment decision‑support platform that analyzes how a patient’s genetics affect responses to medications for behavioral health and chronic pain. GeneSight evaluates a patient’s cheek swab against over 785,000 genetic–medication permutations and reports on 38 FDA‑approved medications across depression, PTSD, bipolar disorder, schizophrenia and other mental health conditions. Results are delivered in an actionable color‑coded report available 36 hours after Assurex receives a patient sample. The company also offers financial assistance programs for eligible patients. Led by President and CEO Virginia C. Drosos, Assurex is using proceeds from a $30M equity financing to support increased clinical adoption and further development of its GeneSight products. Assurex Health is a Mason, OH–based personalized medicine company that provides clinically-relevant individualized genetic information to help physicians select medications for depression, anxiety, chronic pain, ADHD and other neuropsychiatric disorders. Its core product is the GeneSight® suite, built on proprietary pharmacogenomics technology combined with evidence-based medicine and clinical pharmacology. The company has licensed patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center. Led by CEO James S. Burns, Assurex intends to use the proceeds from its financing to support increasing clinical adoption of its GeneSight products. The company secured a $32M financing comprising a $25M term and revolving credit facility and a $7M equity financing from existing investors.

Total raised

$109M

Funding rounds

7

Latest round

Series D

Latest activity

Dec 2015